News

UK Biotech & Life Sciences News

Follow the latest UK life sciences company news, including biotech funding rounds, pharma partnerships, product launches, clinical updates, infrastructure projects and commercial announcements.

Latest updates
Showing 145–156 of 243 stories

AviadoBio Presents Dose-Dependent CSF Progranulin Data from Phase 1/2 ASPIRE-FTD Trial

AviadoBio has presented preliminary Phase 1/2 ASPIRE-FTD data for AVB-101, its gene therapy for FTD-GRN, showing dose-dependent increases in CSF progranulin across four cohorts, with 12-week rises of 36% and 90% over baseline in the third and fourth. The trial has dosed 17 patients, with no serious adverse events related to treatment and no immunosuppression required.

Cerevance, positive Phase 3 ARISE results for solengepras in Parkinson's disease

Cerevance has reported that its Phase 3 ARISE trial of once-daily oral solengepras met its primary endpoint in Parkinson's disease with motor fluctuations. In 341 patients, the 150 mg dose reduced daily OFF time by 0.61 hours versus placebo at Week 12 (p=0.0350), with improvements also seen in ON time without troublesome dyskinesia and MDS-UPDRS Part II. The company plans to meet the FDA to discuss a path to a New Drug Application.

Avacta Raises £12.5M to Extend Cash Runway into Q2 2027

Avacta has raised £12.5 million through a placing and subscription at 68p per share, a discount of about 5.6% to the previous closing price, with its Chairman and three other directors among the subscribers. The funds extend its cash runway into Q2 2027, covering the continuing Phase 1b trial of AVA6000, first efficacy data for AVA6103 in H1 2027, and selection of a clinical candidate for its dual-payload programme AVA6207.

Resolution Therapeutics to Present Interim EMERALD Data on RTX001 at AASLD 2026

Resolution Therapeutics will present interim data from its EMERALD trial of RTX001 as a late-breaker at AASLD 2026 in Denver on 8 November. EMERALD is a first-in-human, single-arm study of the regenerative macrophage therapy in 15 patients with end-stage liver disease recovering from recent decompensation, at centres in the UK and Spain.